Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
2.970
-0.140 (-4.50%)
At close: Nov 4, 2024, 4:00 PM
2.900
-0.070 (-2.36%)
After-hours: Nov 4, 2024, 7:53 PM EST
Purple Biotech Employees
Purple Biotech had 20 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$801,550
Market Cap
5.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Biofrontera | 85 |
Biomerica | 64 |
Intelligent Bio Solutions | 50 |
Windtree Therapeutics | 20 |
Adial Pharmaceuticals | 7 |
Portage Biotech | 7 |
Xenetic Biosciences | 4 |
Hoth Therapeutics | 3 |
PPBT News
- 15 hours ago - Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death - GlobeNewsWire
- 10 days ago - Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 25 days ago - Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 6 weeks ago - Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 - GlobeNewsWire
- 2 months ago - Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule - GlobeNewsWire
- 4 months ago - Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 - GlobeNewsWire